atumelnant
CRN04894-04
Phase 2 small_molecule active
Quick answer
atumelnant for Cushing Syndrome is a Phase 2 program (small_molecule) at Crinetics Pharmaceuticals Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Crinetics Pharmaceuticals Europe GmbH
- Indication
- Cushing Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active